Arcutis Biotherapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ARQT Nasdaq 2830 www.arcutis.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Arcutis Biotherapeutics, Inc.

Wall Street Analysts Believe Arcutis Biotherapeutics (ARQT) Could Rally 37.43%: Here's is How to Trade - Jan 16th, 2025 2:55 pm
Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160 Million - Jan 12th, 2025 1:30 pm
High Growth Tech Stocks In The United States To Watch - Jan 9th, 2025 6:04 pm
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 6th, 2025 9:00 pm
Here's Why Arcutis Stock More Than Doubled in Market Value in One Year - Jan 3rd, 2025 6:28 pm
What Awaits These 4 Biotech Stocks That More Than Doubled in 2024 - Dec 26th, 2024 3:29 pm
Arcutis Submits ZORYVE® (roflumilast) Cream 0.05% Supplemental New Drug Application to the FDA for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis - Dec 16th, 2024 1:00 pm
High Growth Tech Stocks To Watch In December 2024 - Dec 6th, 2024 6:07 pm
Arcutis Announces Promotions on Executive Management Team - Dec 3rd, 2024 1:00 pm
Does Arcutis Biotherapeutics (ARQT) Have the Potential to Rally 60.12% as Wall Street Analysts Expect? - Nov 27th, 2024 2:55 pm
Arcutis Biotherapeutics, Inc. (ARQT) Now Trades Above Golden Cross: Time to Buy? - Nov 27th, 2024 2:55 pm
Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 200-Day Moving Average - Nov 20th, 2024 2:30 pm
Arcutis Biotherapeutics, Inc. (ARQT) Crossed Above the 50-Day Moving Average: What That Means for Investors - Nov 20th, 2024 2:30 pm
Bears are Losing Control Over Arcutis Biotherapeutics (ARQT), Here's Why It's a 'Buy' Now - Nov 19th, 2024 2:55 pm
Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 20-Day Moving Average - Nov 19th, 2024 2:35 pm
Arcutis’ ZORYVE® (roflumilast) Awarded Best Eczema Treatment by Glamour - Nov 13th, 2024 1:00 pm
Wall Street Analysts See a 70.33% Upside in Arcutis Biotherapeutics (ARQT): Can the Stock Really Move This High? - Nov 11th, 2024 2:55 pm
Arcutis Biotherapeutics Third Quarter 2024 Earnings: Beats Expectations - Nov 8th, 2024 10:28 am
Arcutis Biotherapeutics Inc (ARQT) Q3 2024 Earnings Call Highlights: Robust Growth and ... - Nov 7th, 2024 7:23 am
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q3 Loss, Tops Revenue Estimates - Nov 6th, 2024 10:15 pm